CSL Behring biotherapies are used in the treatment of rare and serious medical conditions. Biotherapies are derived from either human plasma or their recombinant equivalents. Biotherapies have a wide variety of therapeutic uses. In different product forms, they are used to treat coagulation disorders, immune deficiencies and Alpha1-antitrypsin deficiency, a type of hereditary emphysema, among other disorders. They are also used in critical care settings to treat shock, burns, sepsis and to help heal wounds.
Plasma is the portion of blood that remains after red cells, leukocytes (white blood cells) and platelets are removed. Plasma consists of water, salts, albumin, antibodies, enzymes and other proteins. Plasma proteins clot blood, fight diseases and perform other critical functions.
By owning and operating CSL Plasma – one of the largest and most sophisticated plasma collection networks in the world – and by working closely with organisations that produce recovered plasma, CSL Behring is thoroughly committed to controlling the quality of the human plasma used to make biotherapies. In addition to plasma, some of our therapies use recombinant DNA technology. With this technology, proteins are synthesised in genetically engineered cell lines.
UK/CORP/15-0012b Date of preparation: July 2015